A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

Carrying out clinical trials of salbutamol hydrochloride combined with immunotherapy and castration for the treatment of prostate cancer is of great significance. Firstly, it can verify the efficacy and safety of this combination in the treatment of prostate cancer, providing a scientific basis for its clinical application. Secondly, through clinical trials, the mechanism of action of salbutamol hydrochloride combined with immunotherapy can be further studied. Finally, this clinical trial can further expand the treatment strategies for prostate cancer.

Trial Details

NCT ID
NCT07250542
Phase
PHASE2
Sponsor
baotai Liang
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Fasudil hydrochloride combined with immunotherapy
Locations (sample)
  • Nanjing, China|32.06167,118.77778

Key Eligibility Criteria

  • Age ≥ 18 years and \< 85 years;
  • Patients who have failed at least one chemotherapy regimen containing docetaxel and one standard novel endocrine therapy;
  • Diagnosed with CRPC, defined as: after continuous castration therapy, the castration level of testosterone is \< 50 ng/ml; disease progression with…
  • Imaging evidence indicates bone metastatic disease and/or measurable non-bone metastatic disease (lymph nodes or internal organs); Expected surviva…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →